Classics in chemical neuroscience: Fluoxetine (Prozac)

ACS Chemical Neuroscience

Volumn 5, Issue 1, 2014, Pages 14-23

  Wenthur, Cody J ^a   Bennett, Megan R ^a   Lindsley, Craig W ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

antidepressant; depression; Fluoxetine; Prozac; serotonin; SSRI

Indexed keywords

FLUOXETINE;

DEPRESSION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NEUROSCIENCE; PHARMACOLOGY; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION;

EID: 84892736549     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn400186j     Document Type: Review

References (110)

1. For up-to date information on depression from the National Institute of Mental Health, see: www.nimh.nih.gov/health/topics/depression.
2. Smith, K. (2011) Trillion dollar brain drain Nature 478, 5-8
3. Artigas, F. (2013) Future directions for serotonin and antidepressants ACS Chem. Neurosci. 4, 5-8
4. American Psychiatric Association. ((2013) Diagnostic and Statistical Manual of Mental Disorders, 5 th ed., American Psychiatric Press, Washington, DC.
5. Lader, M. H. (1998) The Management of Depression (Checkley, S., Ed.), pp 18-211, Blackwell Press, Oxford, U.K.
6. Glennon, R. A. and Iversen, L. (2010) Antidepressants. In Burger's Medicinal Chemistry, Drug Discovery and Development: CNS Disorders (Abraham, D. J. and Rotella, D. P., Eds.), 7 th ed., pp 219-264, John Wiley & Sons, Hoboken, NJ.
7. Kessler, R. C., Chiu, W. T., Demler, O., and Walter, M. S. (2005) Prevalence, severity and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication Arch. Gen. Psychiatry 62, 617-627
8. Sullivan, P. F., Neale, M. C., and Kendler, K. S. (2000) Genetic epidemiology of major depression: review and meta-analysis Am. J. Psychiatry 157, 1552-1562
9. Moret, C. and Briley, M. (1992) Effect of antidepressant drugs on monamine synthesis in brain in vivo Neuropharmacology 31, 679-684
10. Culpepper, L. (2010) Why do you need to move beyond first-line therapy for major depression? J. Clin. Psychiatry 71, 4-9
11. Hodes, G. E. and Russo, S. J. (2012) The neurobiology of depression and anxiety: how do we change from models of drug efficacy to understanding mood and anxiety disorders? In Drug Discovery for Psychiatric Disorders (Rankovic, Z., Bingham, M., Nestler, E. J., and Hargreaves, R., Eds.), pp 159-183, The Royal Society of Chemistry, Cambridge, U.K.
12. Metzner, R. J. (2013) The impact of neurochemical mediators on antidepressant effectiveness ACS Chem. Neurosci. 4, 1245-1248
13. Gelenberg, A. G., Freeman, M. P., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., and Van Rhoads, R. S. (2010) Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third ed., American Psychiatric Association, Arlington, VA.
14. For societal and workplace impact of depression, see: www.caremanagementfordepression.org.
15. Bernois, G. E. (1998) Melancholia and depression during the 19th century: A conceptual history Br. J. Psych. 153, 298-304
16. For information on the WHO-ICD10, see: www.who.int.ICD-10.
17. Molloy, B. and Schmiegel, K. K. (1982) Aryloxyphenylpropylamines. US 4,314,081 (Eli Lilly and Company).
18. Wong, D. T., Perry, K. W., and Bymaster, F. P. (2005) The discovery of fluoxetine hydrochloride (Prozac) Nat. Rev. Drug Discovery 4, 764-774
19. Wong, D. T., Bymaster, F. P., and Engleman, E. A. (1995) Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug (in US): twenty years since its first publication Life Sci. 57, 411-441
20. Stark, P. and Hardison, C. D. (1985) A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder J. Clin. Psychiatry 46, 53-58
21. Wong, D. T., Horng, J. S., Bymaster, F. P., Hauser, K. L., and Molloy, B. B. (1974) A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p -trifluoromethylphenoxy)- N -methyl-3-phenylpropylamine Life Sci. 15, 471-479
22. Fuller, R. W., Perry, K. W., and Molloy, B. B. (1974) Effect of an uptake inhibitor on serotonin metabolism in rat brain: studies with 3-(p- trifluoromethylphenoxy)- N -methyl-3-phenylpropylamine (Lilly 110140) Life Sci. 15, 1161-1171
23. Fuller, R. W., Wong, D. T., and Robertson, D. W. (1991) Fluoxetine, a selective inhibitor of serotonin uptake Med. Res. Rev. 11, 17-34
24. Wong, D. T., Bymaster, F. P., Horng, J. S., and Molloy, B. B. (1975) A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p- trifluoromethylphenoxy)- N -methyl-3-phenylpropylamine J. Pharmacol. Exp. Ther. 193, 804-811
25. Robertson, D. W., Krushinski, J. H., Fuller, R. W., and Leander, J. D. (1988) Absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor J. Med. Chem. 31, 1412-1417
26. Li, J. J., Johnson, D. S., Sliskovic, D. R., and Roth, B. D. (2004) Antidepressants. In Contemporary Drug Synthesis, pp 125-145, John Wiley & Sons, Hoboken, NJ.
27. Corey, E. J. and Reichard, G. A. (1989) Enantioselective and practical synthesis of R- and S-fluoxetines Tetrahedron Lett. 30, 5207-5210
28. Sakuraba, S. and Achiwa, K. (1995) Asymmetric reactions catalyzed by chiral metal complexes. LXVI. Efficient asymmetric hydrogenation of β- and γ-amino ketone derivatives leading to practical syntheses of fluoxetine and eprozinol Chem. Pharm. Bull. 43, 784-753
29. Gao, Y. and Sharpless, K. B. (1988) Asymmetric synthesis of both enantiomers of tomoxetine and fluoxetine. Selective reduction of 2,3-epoxycinnamyl alcohol with Red-Al J. Org. Chem. 53, 4081-4084
30. Pandey, R. K., Fernandes, R. A., and Kumar, P. (2002) An asymmetric dihydroxylation route to enantiomerically pure norfluoxetine and fluoxetine Tetrahedron Lett. 43, 4425-4426
31. Ali, I. S. and Sudalai, A. (2002) Pd-Catalyzed kinetic resolution of benzylic alcohols: a practical synthesis of (R)-tomoxetine and (S)-fluoxetine hydrochlorides Tetrahedron Lett. 43, 5435-5436
32. Miles, W. H., Fialcowitz, E. J., and Halstead, E. S. (2001) Enantioselective synthesis of (S)- and (R)-fluoxetine hydrochloride Tetrahedron 57, 9925-9929
33. Trost, B. M., Fraisse, P. L., and Ball, Z. T. (2002) A stereospecific ruthenium-catalyzed allylic alkylation Angew. Chem., Int. Ed. 41, 1059-1061
34. Kumar, A., Ner, D. H., and Dike, S. Y. (1991) A new chemoenzymatic enantioselective synthesis of R -(-)-tomoxetine, (R)- and (S)-fluoxetine Tetrahedron Lett. 32, 1901-1904
35. Chenevert, R., Fortier, G., and Bel Rhlid, R. (1992) Asymmetric synthesis of both enantiomers of fluoxetine via microbiological reduction of ethyl benzoylacetate Tetrahedron 48, 6769-6776
36. Schneider, M. P. and Goergens, U. (1992) An efficient route to enantiomerically pure antidepressants: tomoxetine, nisoxetine and fluoxetine Tetrahedron: Asymmetry 3, 525-528
37. Bracher, F. and LItz, T. (1996) An efficient chemoenzymatic route to the antidepressants (R)-fluoxetine and (R)-tomoxetine Bioorg. Med. Chem. 4, 877-880
38. Liu, H.-L., Hoff, B. H., and Anthonsen, T. (2000) Chemoenzymatic synthesis of the non-tricyclic antidepressants Fluoxetine, Tomoxetine and Nisoxetine J. Chem. Soc., Perkins Trans. 1 1767-1769
39. Kamal, A., Ramesh Khanna, G. B., and Ramu, R. (2002) Chemoenzymatic synthesis2 of both enantiomers of fluoxetine, tomoxetine and nisoxetine: lipase-catalyzed resolution of 3-aryl-3-hydroxypropanenitriles Tetrahedron: Asymmetry 13, 2039-2051
40. Ahmed-Omer, B. and Sanderson, A. J. (2011) Preparation of fluoxetine by multiple flow processing steps Org. Biomol. Chem. 9, 3854-3862
41. Prozac [package insert] Eli Lilly & Co, Indianapolis, IN, 2013. For more information see, www.lilly.com.
42. For information on sales and trade names, see: www.imshealth.com.
43. Hiemke, C. and Hartter, S. (2000) Pharmacokinetics of selective serotonin reuptake inhibitors Pharmacol. Ther. 85, 11-28
44. Margolis, J. M., O'Donnell, J. P., Mankowski, D. C., Ekins, S., and Obach, R. S. (2000) (R)-,(S)- andracemic fluoxetine N -demethylation by human cytochrome P450 enzymes Drug Metab Dispos. 28, 1187-1191
45. Mandrioli, R., Forti, G. C. F., and Raggi, M. A. (2006) Fluoxetine metabolism and pharmacological interactions: The role of cytochrome P450 Curr. Drug Metab. 7, 127-133
46. Gossen, D., de Suray, J.-M., Vandenhende, F., Onkenlix, C., and Gangji, D. (2002) Influence of fluoxetine on olanzapine pharmacokinetics AAPS PharmSci. 4, 1-6
47. Thayer, A. (2000) Eli Lilly pulls the plug on Prozac isomer drug C&E News 78, 8
48. Braddock, M. (2005) Prozac C&E News 83, 104
49. Dengler, H. J. and Titus, E. O. (1961) The effect of drugs on the uptake of isotopic norepinephrine in various tissues Biochem. Pharmacol. 8, 64
50. 3-norepinephrine J. Pharamcol. Exp. Ther. 134, 146-153
51. Glowinski, J. and Axelrod, J. (1964) Inhibition of uptake of tritiated-noradrenaline in the intact rat brain by imipramine and structurally related compounds Nature 204, 1318-1319
52. Iversen, L. L. (1971) Role of transmitter uptake mechanisms in synaptic neurotransmission Br. J. Pharmacol. 41, 571-591
53. Carlsson, A., Fuxe, K., Hamberger, B., and Lindqvist, M. (1966) Biochemical and histochemical studies on the effects of imipramine-like drugs and (+)-amphetamine on central and peripheral catecholamine neurons Acta Physiol. Scand. 67, 481-497
54. Carlsson, A., Corrodi, H., Fuxe, K., and Hökfelt, T. (1969) Effects of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-α-ethylmetatyramine Eur. J. Pharmacol. 5, 357-366
55. Receptor binding profiles were generously provided by the National Institute of Mental Health's Psychoactive Drug Screening Program, Contract # HHSN-271-2008-00025-C (NIMH PDSP). The NIMH PDSP is Directed by Bryan L. Roth, M.D., Ph.D. at the University of North Carolina at Chapel Hill and Project Officer Jamie Driscol at NIMH, Bethesda, MD.
56. Perry, K. W. and Fuller, R. W. (1992) Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum Life Sci. 50, 1683-1690
57. Fuller, R. W., Snoddy, H. D., and Molloy, B. B. (1975) Potentiation of the L-5-hydroxytryptophan-induced elevation of plasma corticosterone levels in rats by a specific inhibitor of serotonin uptake Res. Commun. Chem. Pathol. Pharmacol. 10, 193-196
58. Beasley, C. M., Jr., Nilsson, M. E., Koke, S. C., and Gonzales, J. S. (2000) Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose J. Clin. Psychiatry 61, 722-728
59. Andrews, A. M. (2009) Does chronic antidepressant treatment increase extracellular serotonin? Front. Neurosci. 3, 246-247
60. Luellen, B. A., Gilman, T. L., and Andrews, A. M. (2010) Presynaptic adaptive response to constitutive versus acute pharmacologic inhibition of serotonin uptake. In Experimental Models in Serotonin Transporter Research (Kalueff, A. V. and LaPorte, J. L., Eds.), pp 1-42, Cambridge University Press, Cambridge.
61. Wernicke, J. F. (1985) The side effect profile and safety of fluoxetine J. Clin. Psychiatry 46, 59-67
62. Castren, E. and Rantamaki, T. (2010) The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity Dev. Neurobiol. 70, 289-297
63. Price, R. B., Nock, M. K., Charney, D. S., and Mathew, S. J. (2009) Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression Biol. Psychiatry 66, 522-526
64. Pinna, G., Costa, E., and Guidotti, A. (2006) Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake Psychopharmacology 186, 362-372
65. For more information on FDA approved indications, see: www.fda.gov.
66. Preskorn, S. H. (2010) CNS drug development: Part I: The early period of CNS drugs J. Psychiatr. Pract. 16, 334-339
67. Delay, J., Deniker, P., Tardieu, Y., and Lempereire, T. (1955) Neuroplegic medications and cures in psychiatry: preliminary trials with reserpine; comparison with the effects of chlorpromazine La Presse Medicale 63, 663-665
68. Blair, D. (1960) Chlorpromazine and schizophrenia: The role of the practitioner The Practitioner 184338-184344
69. Markowe, M., Steinert, J., and Heyworth-Davis, F. (1967) Insulin and chlorpromazine in schizophrenia: a ten year comparative survey Br. J. Pyschiatry 113, 1101-1106
70. Azine, H. and Vispo, R. H. (1958) Imipramine; a new antidepressant compound Am. J. Psychiatry 115, 245-246
71. Kuhn, R. (1958) The treatment of depressive states with G 22355 (imipramine hydrochloride) Am. J. Psychiatry 115, 459-464
72. Feldman, P. E. (1959) Preliminary report on imipramine (tofranil). (1959) Am. J. Psychiatry 115, 1117-1118
73. Lader, M. (2004) Handb. Exp. Pharmacol. 157, 185-208 (Antidepressants)
74. Gilman, P. K. (2007) Tricyclic antidepressant pharmacology and therapeutic drug interactions updated Br. J. Pharmacol. 151, 737-748
75. Kuhn, R. (1970) In Discoveries in biological psychiatry (Ayd, J. F. and Blackwell, B., Eds.), pp 205-217, Lippincott, Philadelphia, PA.
76. Vaisberg, M. and Saunders, J. C. (1961) Amitriptyline in the treatment of depressive states (a pilot study) Dis. Nerv. Syst. 22334-22338
77. Barsa, J. A. and Saunders, J. C. (1961) Amitriptyline (Elavil), a new antidepressant Am. J. Psychiatry 117730-117740
78. Sulser, F., Watts, J., and Brodie, B. B. (1962) On the mechanism of antidepressant action of imipramine-like drugs Ann. N.Y. Acad. Sci. 96, 279-286
79. Ross, S. B. and Renyi, A. L. (1967) Inhibition of tritiated catecholamines by antidepressants and related agents Eur. J. Pharmacol. 2, 181-186
80. Bourin, M. (1990) Is it possible to predict the activity of a new antidepressant in animals with simple psychopharmacological tests? Fundam. Clin. Pharmacol. 4, 49-64
81. Corrodi, H. and Fuxe, K. (1968) The effect of imipramine on central monoamine neurons J. Pharm. Pharmacol. 20, 230-231
82. Ross, S. B. and Renyi, A. L. (1975) Tricyclic antidepressant agents. I. Comparison of the inhibition of the uptake of 3-H-noradrenaline and 14-C-5-hydroxytryptamine in slices and crude synaptosome preparations of the midbrain-hypothalamus region of the rat brain Acta Pharmacol. Toxicol. 36, 382-394
83. Viewig, W., Victor, R., and Wood, M. A. (2004) Tricyclic antidepressants, QT interval prolongation and torsade de pointes Psychosomatics 45, 371-377
84. West, E. D. and Dally, P. J. (1959) Effects of iproniazid in depressive syndromes Br. Med. J. 1, 1491-1494
85. Remick, R. A. and Froese, C. (1990) Monoamine oxidase inhibitors: Clinical review Can. Fam. Physician 36, 1151-1155
86. Himmelhoch, J. M., Fuchs, C. Z., and Symons, B. J. (1982) A double-blind study of tranylcypromine treatment of major anergic depression J. Nerv. Ment. Dis. 170, 628-634
87. Rowan, P. R., Paykel, E. S., and Parker, R. R. (1982) Phenelzine and amitriptyline: effects on symptoms of neurotic depression Br. J. Psychiatry 140, 475-483
88. Blackwell, B., Marley, E., Price, J., and Taylor, D. (1967) Hypertensive iteractions between monoamine oxidase inhibitors and foodstuffs Br. J. Psychiatry 113, 349-365
89. Thase, M. E. (2012) The role of monoamine oxidase inhibitors in depression treatment guidelines J. Clin. Psychiatry 73, 10-16
90. Weil-Malherbe, H. and Szara, S. I. (1971) The Biochemistry of Functional and Experimental Psychosis, pp 57-76, Thomas, Springfield, IL.
91. Shaw, D. M., Camps, F. E., and Eccleston, E. (1967) 5-Hydroxytryptamine in the hind brain of depressive suicides Br. J. Psychiatry 113, 1407-1411
92. Bourne, H. R., Bunney, W. E., Jr., Colburn, R. W., Davis, J. M., Davis, J. N., Shaw, D. M., and Coppen, A. J. (1968) Noradrenaline, 5-hydroxytryptamine, and 5-hydroxyindoleacetic acid in hindbrains of suicidal patients Lancet 2, 805-808
93. Coppen, A., Shaw, D. M., and Farrell, J. P. (1963) Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan Lancet 1, 79-81
94. Pare, C. M. (1963) Potentiation of monoamine oxidase inhibitors by tryptophan Lancet 2, 527-528
95. Ashcroft, G. W., Crawford, T. B., Eccleston, D., Sharman, D. F., MacDougall, E. J., Stanton, J. B., and Binns, J. K. (1966) 5-hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological diseases Lancet 2, 1049-1052
96. Heel, R. C., Morley, P. A., Brogden, R. N., Carmine, A. A., Speight, T. M., and Avery, G. S. (1982) Zimelidine: a review of its pharmacological properties and therapeutic efficacy in depressive illness Drugs 24, 169-206
97. Bengtsson, B. O., Wiholm, B. E., Myrhed, M., and Walinder, J. (1994) Adverse experiences during treatment with zimelidine on special license in Sweden Int. Clin. Pharmacol. 9, 55-61
98. Stokes, P. E. and Holtz, A. (1997) Fluoxetine tenth anniversary update: the progress continues Clin. Ther. 19, 1135-1250
99. Stokes, P. E. (1998) Ten years of fluoxetine Depression Anxiety 8, 1-4
100. For publications relating to fluoxetine, see: http://www.ncbi.nlm.nih. gov/pubmed/ (search string fluoxetine).
101. For publications relating to fluoxetine, see: http://www.webofknowledge. com (search string fluoxetine).
102. Lacasse, J. R. and Leo, J. (2005) Serotonin and depression: A disconnect between the advertisements and the scientific literature PLoS Med 2, e392
103. Moore, A. (2007) Eternal sunshine. The Observer, 12 May 2007.
104. Newsweek, 26 March 1990.
105. Fortune, 22 November 1999.
106. Wurtzel, E. (1995) Prozac Nation, Riverhead Books, New York.
107. For the online Webster's dictionary, see: http://www.merriam-webster.com/ (search Prozac).
108. Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierneberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., McGrath, P. J., Rosenbaum, J. F., Sackeim, H. A., Kupfer, D. J., Luther, J., and Fava, M. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STARD report Am. J. Psychiatry 163, 1905-1917
109. Wisniewski, S. R., Rush, A. J., Bryan, C., Shelton, R., Trivedi, M. H., Marcus, S., Husain, M. M., Hollon, S. D., and Fava, M. (2007) STARD Investigators. Comparison of quality of life measures in a depressed population J. Nerv. Ment. Dis. 195, 219-25
110. Wenthur, C. J. and Lindsley, C. W. (2013) Classics in Chemical Neuroscience: Clozapine ACS Chem. Neurosci. 4, 1018-1025